Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(03): 185-187
DOI: 10.4103/0971-5851.103152
CASE REPORT

Successful treatment of vincristine induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia

Kamalakshi G Bhat
Department of Pediatrics, Kasturba Medical Collge, Mangalore, Karnataka, India
,
Vikram Singhal
Department of Pediatrics, Kasturba Medical Collge, Mangalore, Karnataka, India
,
Anupama S Borker
Department of Pediatrics, Kasturba Medical Collge, Mangalore, Karnataka, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Vincristine is used in the treatment of solid tumors, lymphoma and leukemia in children. The dose-limiting toxicity is its neurotoxicity. We describe a 2-year-old girl with acute lymphoblastic leukemia who developed vincristine-induced polyneuropathy with bilateral ptosis and recovered on treatment with pyridoxine and pyridostigmine.

Keywords

Polyneuropathy - ptosis - pyridoxine and pyridostigmine - vincristine


Publication History

Article published online:
02 August 2021

© 2012. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lash SC, Williams CP, Marsh CS, Crithchley C, Hodgekins PR, MacKie EJ. Acute sixth-nerve palsy after vincristine therapy. J APOS 2004;8:67-8.
  • 2 Bay A, Yilmaz C, Yilmaz N, Oner AF. Vincristine induced cranial polyneuropathy. Indian J Pediatr 2006;73:531-3.
  • 3 Muller L, Kramm CM, Tenenbaum T, Wessalowski R, Gobel U. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. Pediatr Blood Cancer 2004;42:287-8.
  • 4 Ozyurek H, Turker H, Akbalik M, Bayrak AO, Ince H, Duru F. Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy. Pediatr Hematol Oncol 2007;24:447-52.
  • 5 Ozgur D, Gulsun T, Volkan H. Treatment of vincristine induced cranial polyneuropathy. J Pediatr Hematol Oncol 2005;27:241-2.
  • 6 Gomber S, Dewan P, Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 2010;77:97-100.
  • 7 Kumar N. Nutritional neuropathies. Neurol Clin 2007;25:209-55.
  • 8 Weber GA, Sloan P, Davies D. Nutritionally induced peripheral neuropathies. Clin Podiatr Med Surg 1990;7:107-28.
  • 9 Wang MS, Wu Y, Culver DG, Glass JD. Pathogenesis of axonal degeneration: Parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol 2000;59:599-606.
  • 10 Chan JD. Pharmacokinetic drug interactions of vinca alkaloids summary of case reports. Pharmacotherapy 1998;18:1304-7.
  • 11 Jackson DV Jr, Pope EK, McMahan RA, Cooper MR, Atkins JN, Callahan RD, et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986;4:37-41.